Transform Your Portfolio with Cancer Therapeutics Development
Are you ready to possibly make a difference with your investments? It may be time to consider the exciting realm of cancer therapeutics development for your investment portfolio!
Why Consider Investing in Cancer Therapeutics Development?
Cancer, a global menace, demands our attention and action. With its prevalence soaring as our population ages, there's never been a more critical time to invest in the fight against it. While strides have been made in diagnosis and treatment, the battle is far from over.
But why should you join the cause as an investor?
1. Health Crisis Demands Innovative Solutions
Cancer's grip on humanity is tightening, with over 19 million new cases in 2020 alone.[1] In the United States, over 1.9 million were estimated to receive diagnoses in 2023 with projections indicating a 27% increase by 2040.[2] It's not just a statistic; it's a call to action!
2. Seize the Opportunity in Biotech
The Nasdaq Biotech Index's recent downturn can present an enticing opportunity. With negative investor sentiment and companies trading below their cash value, now may be the time to explore the untapped potential within the biotech sector. Could this be your chance to ride the potential wave of resurgence?
3. Leading the Charge in Cancer Therapeutics Advancement
Oncology isn't standing still. From precision medicine to groundbreaking immunotherapy techniques, the landscape is evolving rapidly. With AI-powered screening and DNA analysis, the possibilities are limitless. It's not just about treatments; it's about rewriting the rules of engagement.
4. Unveiling the Potential Opportunity
As cancer cases surge, so does the demand for better diagnostics and therapies. Companies at the forefront of innovation stand to revolutionize the field. Investing in these pioneers may not just be financially savvy; it may also be a chance to be part of something bigger than ourselves.
How Can Investors Get Involved?
Introducing CNCR: A gateway to cancer therapeutics investments.
Consider CNCR For Your Portfolio
CNCR aims to provide exposure to the companies at the vanguard of oncological research that may have the potential to develop groundbreaking cancer therapeutics. This may provide an attractive investment opportunity for individuals.
CNCR may allow you to make a difference while making profits. Join us in the fight against cancer and expand your investment portfolio today!
The Range Cancer Therapeutics ETF (CNCR)
The Range Cancer Therapeutics ETF (CNCR) seeks to track the performance, before fees and expenses, of the Range Cancer Therapeutics Index. The index aims to track the performance of a portfolio of stocks that are involved in the development and distribution of cancer drugs and treatments.
[1] Oncology Market, Precedence Research, June 2023
[2] Cancer Facts & Figures, American Cancer Society, 2023
Disclosures
All investing involves risk, and asset allocation and diversification do not guarantee a profit or protection against a loss. The investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, might be worth more or less than their original cost. ETFs are subject to risks similar to those of stocks, as well as other risks specific to the particular ETF.
ETF shares are traded on exchanges and are traded and priced throughout the trading day. ETFs permit an investor to purchase a selling interest in a portfolio of stocks throughout the trading day. Because ETFs trade on an exchange, ETF shares are bought and sold at market price (not NAV). The prices of ETFs may sometimes vary significantly from the NAVs of an ETFs’ underlying securities. Brokerage commissions will reduce returns.
The Fund is a recently organized investment company with no operating history. As a result, prospective investors have no track record or history on which to base their investment decision. Moreover, investors will not be able to evaluate the Fund against one or more comparable funds on the basis of relative performance until the Funds has established a track record.
The Range Cancer Therapeutics ETF is offered by prospectus. Carefully consider the investment objectives, risks, charges, and expenses. This and other important information can be found in the CNCR ETF prospectus, which should be read carefully before investing and can be obtained here or by calling 1-800-617-0004.
Exchange Traded Concepts, LLC serves as the investment advisor to the Fund. The Fund is distributed by Quasar Distributors, LLC. Quasar is not affiliated with Exchange Traded Concepts, LLC.
Cancer Therapeutics Companies Risk. The success of Cancer Therapeutics Companies heavily depends on the outcomes of clinical trials and obtaining necessary regulatory approvals for the development of new drugs and other treatments for cancer-related conditions. These companies face risks related to the failure of clinical trials, unforeseen safety issues, delays in the regulatory approval process, or failure to obtain approvals altogether. Cancer Therapeutics Companies are highly dependent on the development, procurement and marketing of drugs and the protection and exploitation of intellectual property rights. Changes in healthcare policies, reimbursement rates, patent laws, or regulations governing drug development and commercialization can significantly impact industry and individual companies. These changes may affect profitability, market access, and the viability of certain products or technologies.
